 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 July 1998 | Volume 129 Issue 2 | Pages 100-104
Background: The therapeutic outcome for unresectable, locally advanced, malignant thymoma has been poor.
Objective: To improve tumor resectability and patient survival rates by studying a multimodal approach to therapy for unresectable malignant thymoma.
Design: Prospective cohort study.
Setting: Tertiary care cancer center.
Participants: All eligible patients had newly diagnosed, histologically proven, unresectable malignant thymoma.
Intervention: The treatment regimen consisted of induction chemotherapy (three courses of cyclophosphamide, doxorubicin, cisplatin, and prednisone), surgical resection, postoperative radiation therapy, and consolidation chemotherapy (three courses of cyclophosphamide, doxorubicin, cisplatin, and prednisone). Tissue samples were taken at the time of surgical resection for assessment of tumor necrosis and Ki-67 expression.
Measurements: Tumor response and resectability (both overall and after induction chemotherapy) and disease-free survival rate in patients who received multimodal therapy.
Results: 13 patients were consecutively enrolled from February 1990 to December 1996, and 12 evaluable patients were assessed for response. Disease responded to induction chemotherapy completely in 3 patients (25%) and partially in 8 patients (67%); 1 patient had a minor response (8%). Eleven patients had surgical resection; 1 refused surgery. Tumors were removed completely in 9 (82%) and incompletely in 2 (18%) of 11 patients who had been receiving radiation therapy and consolidation chemotherapy. All 12 patients are alive (100% at 7 years), with a median follow-up of 43 months, and 10 patients are disease free (73% disease-free survival at 7 years). A high correlation was seen between tumor necrosis after induction chemotherapy and Ki-67 expression (r = –0.88).
Conclusions: Aggressive multimodal treatment is highly effective and may cure locally advanced, unresectable malignant thymoma.
BRIEF COMMUNICATION
A Multidisciplinary Approach to Therapy for Unresectable Malignant Thymoma
This article has been cited by other articles:
 |
|
 |
|
  C. D. Wright, P. Fidias, N. C.H. Choi, J.-A. O. Shepard, and R. P. Hasserjian Case 16-2007 -- A 61-Year-Old Man with a Mediastinal Mass N. Engl. J. Med., May 24, 2007; 356(21): 2185 - 2193. [Full Text] [PDF]
|
|
|
|
 |
|
 R. F. Riedel and W. R. Burfeind Jr Thymoma: Benign Appearance, Malignant Potential Oncologist, September 1, 2006; 11(8): 887 - 894. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Suzuki, H. Sasaki, O. Kawano, K. Endo, H. Haneda, H. Yukiue, Y. Kobayashi, M. Yano, and Y. Fujii Expression and Mutation Statuses of Epidermal Growth Factor Receptor in Thymic Epithelial Tumors Jpn. J. Clin. Oncol., June 1, 2006; 36(6): 351 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Fang, W. Chen, G. Chen, and Y. Jiang Surgical Management of Thymic Epithelial Tumors: A Retrospective Review of 204 Cases Ann. Thorac. Surg., December 1, 2005; 80(6): 2002 - 2007. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Baran, C. M. Magro, M. A. King, T. E. Williams Jr, and P. Ross Jr Atypical thymoma: A report of seven patients Ann. Thorac. Surg., August 1, 2004; 78(2): 411 - 416. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Rea, G. Marulli, R. Girardi, L. Bortolotti, A. Favaretto, A. Galligioni, and F. Sartori Long-term survival and prognostic factors in thymic epithelial tumours Eur. J. Cardiothorac. Surg., August 1, 2004; 26(2): 412 - 418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. C. Detterbeck and A. M. Parsons Thymic tumors Ann. Thorac. Surg., May 1, 2004; 77(5): 1860 - 1869. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Loehrer Sr, W. Wang, D. H. Johnson, and D. S. Ettinger Octreotide Alone or With Prednisone in Patients With Advanced Thymoma and Thymic Carcinoma: An Eastern Cooperative Oncology Group Phase II Trial J. Clin. Oncol., January 15, 2004; 22(2): 293 - 299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Evoli, C. Minisci, C. Di Schino, F. Marsili, C. Punzi, A. P. Batocchi, P. A. Tonali, G. B. Doglietto, P. Granone, L. Trodella, et al. Thymoma in patients with MG: Characteristics and long-term outcome Neurology, December 24, 2002; 59(12): 1844 - 1850. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Santana, A. Givica, and C. Camacho Best Cases from the AFIP: Thymoma RadioGraphics, October 1, 2002; 22(90001): S95 - 102. [Full Text] [PDF]
|
|
|
|
|
|
S. Umemura, Y. Segawa, K. Fujiwara, I. Takata, N. Seki, Y. Tokuda, K. Eguchi, and K. Mandai A Case of Recurrent Metastatic Thymoma Showing a Marked Response to Paclitaxel Monotherapy Jpn. J. Clin. Oncol., July 1, 2002; 32(7): 262 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rios, J. Torres, P.J. Galindo, M.J. Roca, J.M. Rodriguez, J. Sola, and P. Parrilla Prognostic factors in thymic epithelial neoplasms Eur. J. Cardiothorac. Surg., February 1, 2002; 21(2): 307 - 313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Refaely, D. A. Simansky, M. Paley, M. Gottfried, and A. Yellin Resection and perfusion thermochemotherapy: a new approach for the treatment of thymic malignancies with pleural spread Ann. Thorac. Surg., August 1, 2001; 72(2): 366 - 370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. B. Johnson, T. Y. Eng, G. Giaccone, and C. R. Thomas Jr. Thymoma: Update for the New Millenium Oncologist, June 1, 2001; 6(3): 239 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. R. Thomas, C. D. Wright, and P. J. Loehrer Thymoma: State of the Art J. Clin. Oncol., July 1, 1999; 17(7): 2280 - 2280. [Abstract] [Full Text] [PDF]
|
|
Article
